U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07133425) titled 'A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer' on Aug. 19.
Brief Summary: To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
Study Start Date: Feb. 05, 2026
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
ICI-refractory
Intervention:
DRUG: SAR445877
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....